Insmed Incorporated said that the U.S. Patent and Trademark Office (USPTO) has issued US patent No. 10,251,900, titled “Methods for treating pulmonary non-tuberculous mycobacterial infections,” which is the 10th US patent covering the use of Arikayce amikacin liposome inhalation suspension for the treatment of Mycobacterium avium complex (MAC) lung disease. Arikayce is also protected by five European patents and eight Japanese patents.
In September 2018, the FDA approved Arikayce for the treatment of MAC lung disease in combination with other antibiotics in a limited population. The new patent covers administration of Arikayce with ethambutol and a macrolide antibiotic.
Insmed Chairman and CEO Will Lewis said, “We are very pleased to receive another patent for Arikayce that reinforces our exclusivity in the US to 2035 for methods that align closely with our approved label, further strengthening our global patent portfolio. In addition, as we advance toward regulatory filings for Arikayce in Europe and Japan, we are continuing to pursue intellectual property protection in these and other major markets worldwide.”
Read the Insmed press release.